Encouraging update for cancer vaccines. Pivotal Ph3 trial positive for both RFS and DMFS at interim analysis. Eager to see effect sizes and other details at #ESMO26 merck.com/news/merck-and…
www.merck.com Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met... First and only combination regimen to demonstrate statistically significant and clinically meaningful improvements in RFS and DMFS compared to KEYTRUDA alone for these patients in the adjuvant... 
